PubMed Health⌕ Search

Biomedical subjects

A Paredes

Publications and source records attributed to A Paredes.

125 records · Page 7Linked to original sources
PubMedDate not supplied

Evaluation of butaclamol in chronic schizophrenic patients.

In a double-blind, placebo-controlled study, an attempt was made to evaluate butaclamol in chronic schizophrenic patients using chlorpromazine (CPZ) as the standard comparative drug. With doses up to 50 mg/day, butaclamol was shown to have significant antipsychotic activity comparable to CPZ but with a much higher incidence of extrapyramidal signs. A more reasonable maintenance dose may be in the range of 5 to 20 mg/day. Rebound insomnia was noted again with butaclamol, which warrants further study.

Adult↗
PubMedDate not supplied

Variations in psychosocial functioning associated with patterns of progression in cocaine-dependent men.

This study examined the relationship between patterns of progression of cocaine use and psychosocial functioning in a sample of cocaine-dependent men who were veterans. Four patterns of progression were examined: mild-severe, moderate-severe, mild-moderate-severe, and severe only. Analysis of variance and post hoc analysis with Duncan grouping revealed significant differences among cocaine users with different patterns of progression in terms of negativism, problem index for situations involving unpleasant emotions, problem index for situations involving urges, depression, somatic anxiety, and medical problems in the family. However, there were no significant differences on sensation seeking, confidence to resist taking cocaine in different situations, obsessive compulsiveness, somatization, attention deficit, and social adjustment. Cocaine users with a severe-only pattern of progression were significantly more dysfunctional than those with mild-moderate-severe progression in terms of negativism, problem index for situations involving unpleasant emotions, depression, and somatic anxiety. Cocaine users with mild-moderate-severe progression had significantly less somatic anxiety than those with mild-severe progression and had less negativism and a lower problem index for urges than those with moderate-severe progression. Logistic regression analysis revealed unique behavioral variables associated with different patterns of progression. The implications of these findings for treatment are discussed.

Adaptation, Psychological↗
PubMedDate not supplied

Non-Hodgkin's lymphoma (NHL) of the testicle. A clinicopathologic study of 19 patients.

To investigate the frequency, clinical and anatomopathologic characteristics of non-Hodgkin's Lymphoma (NHL) present in the testicle as primary or secondary disease, we reviewed the files of the Hematology and Pathology Services of the General Hospital of Mexico, from January 1975 to December 1988. We found 681 cases of NHL in the Hematology Service; of these, 388 (57%) were male and 8 (2%) of them presented testicle involvement. Two were considered as primary disease, 4 as systemic disease and 2 as secondary or late complications. The overall mean age was 49 years. According to the New Working Formulation (NWF), 7 cases corresponded to the intermediate grade of malignancy and one to a plasmacytoma. The mean survival time of the whole group was 3.9 months. In the Pathology Department, the files of 203 autopsies of patients with NHL were reviewed; 124 (61%) were male and 11 (8.9%) of them presented testicle infiltration. In two, the testicular involvement was known before death and in 9 it was found at autopsy. In one case the infiltration was located in the epididimus and in other in the spermatic cords. The mean age of these patients was 50.7 years. In 6 cases there was extranodal infiltration other than in the testicle: 1 in the nose, and 1 in the central nervous system. According to the NWF, 1 was classified as of low malignancy grade, 7 were of the intermediate malignancy, and 3 of high malignancy grade.

Humans↗
PubMedDate not supplied

Extraction of light filth from spirulina powders and tablets: collaborative study.

Results are reported for a collaborative study of a method for the extraction of light filth from spirulina (a blue-green alga) powder and tablets. A 50 g portion of either powder or tablets is dispersed in water, and then boiled with dilute HCI solution. Hairs and insect fragments are isolated by wet sieving on a No. 230 sieve, flotation with mineral oil, and washings of the mineral oil in a percolator. Average recoveries by 12 collaborators for tablets and powders were 70.6 and 70.2%, respectively, for 10 rat hair spikes and 68.3 and 84.4%, respectively, for 20 insect fragment spikes. The method has been approved interim official first action.

Cyanobacteria↗
PubMedDate not supplied

[Fluoxetine in the treatment of borderline personality disorder].

OBJECTIVE: This study evaluates the therapeutic effect of fluoxetine, a selective serotonin reuptake inhibitor, in borderline personality disorder. METHOD: 46 patients with borderline personality disorder according to DSM-III-R and Diagnostic Interview for Borderlines (DIB-R) criteria, were given fluoxetine 20-60 mg for seven weeks. They were evaluated each week using Brief Psychiatric Rating Scale (BPRS), Global Assessment of Functioning Scale (GAF), Hamilton Depression Rating Scale (HDRS) and a clinical Impulsivity Scale. RESULTS: There were significant improvements in BPRS, HDRS, GAF and Impulsivity Scale from the first week of the treatment. These improvements continued until the seven week of treatment. The favourable outcome was not only due to the improvement in depression and impulsivity scores, but also to the decline of global psychopathology. CONCLUSIONS: The data suggest that fluoxetine is an effective pharmacologic treatment for borderline personality disorder. These findings support the hypothesis of a 5-HT dysfunction in borderline personality disorder.

Adolescent↗